A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

2014/2/24 12:00

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glimepiride; Drug: Metformin; Drug: Pioglitazone; Drug: Acarbose; Drug: Linagliptin; Drug: Sitagliptin; Drug: Liraglutide; Drug: Insulin Glargine; Drug: Exenatide once weekly (QW); Drug: Exenatide twice daily (BID)
Sponsor: Eli Lilly and Company
Not yet recruiting - verified February 2014

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

2014/1/13 12:00

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin (5 mg); Drug: Ertugliflozin (15 mg); Drug: Placebo; Drug: Metformin; Drug: Sitagliptin; Drug: Glimepiride; Biological: Insulin
Sponsors: Merck Sharp & Dohme Corp.; Pfizer
Not yet recruiting - verified January 2014

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007)

2014/1/9 12:00

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin 5 mg; Drug: Ertugliflozin 15 mg; Drug: Placebo to Ertugliflozin; Other: Glimepiride; Drug: Placebo to Glimepiride; Biological: Basal Insulin; Drug: Metformin
Sponsors: Merck Sharp & Dohme Corp.; Pfizer
Not yet recruiting - verified January 2014

Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment

2013/12/26 12:00

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride; Drug: glargine and metformin
Sponsors: Chongqing Medical University; Qifu Li
Recruiting - verified December 2013

Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride

2013/12/5 12:00

Conditions: Type 2 Diabetes; Hypoglycemia
Interventions: Drug: vildagliptin and metformin (combination); Drug: glimepiride; Drug: Metformin
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified December 2013

MK-8835/PF-04971729 vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

2013/11/25 12:00

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin; Drug: Glimepiride; Drug: Placebo; Drug: Metformin; Drug: Sitagliptin
Sponsor: Merck
Not yet recruiting - verified November 2013

Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

2013/11/15 12:00

Condition: T2DM
Intervention: Drug: Gemigliptin
Sponsor: LG Life Sciences
Not yet recruiting - verified November 2013

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

2013/9/19 12:00

Conditions: Type 2 Diabetes; Cardiovascular Disease
Interventions: Drug: Sitagliptin; Drug: Glimepiride; Drug: Placebo; Drug: Placebo
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Merck
Not yet recruiting - verified September 2013

Incretin and KATP Channels

2013/8/19 12:00

Condition: Healthy Subjects
Intervention: Other: Intradermal injections of GLP-1 and its analogues
Sponsors: Royal Devon and Exeter NHS Foundation Trust; Katarina Kos; University of Exeter
Recruiting - verified August 2013

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

2013/7/25 12:00

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin; Drug: Glimepiride; Drug: Metformin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified July 2013

Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on MAGE in Patients With Type 2 DM

2013/5/24 12:00

Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
Sponsors: LG Life Sciences; LG Life Sciences
Recruiting - verified June 2013

A Study to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

2013/5/23 12:00

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Glimepiride; Drug: MK-3102 Placebo; Drug: Glimepiride Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified May 2013

Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

2013/4/24 12:00

Condition: Type 2 Diabetes
Interventions: Drug: MK-3102; Drug: Sitagliptin; Drug: Placebo to MK-3102; Drug: Placebo to Sitagliptin; Drug: Open-label Metformin; Drug: Open-label Glimepiride
Sponsors: Merck; Merck
Not yet recruiting - verified April 2013

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

2013/4/9 12:00

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875 Placebo; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified April 2013

Pioglitazone Decreases Visceral Fat Metabolism

2013/3/24 12:00

Condition: To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
Intervention: Drug: Pioglitazone vs Glimepiride
Sponsors: Kurume University; Kurume University
Recruiting - verified March 2013

Effects of Vildagliptine and Glimepiride on Glucose Variability

2013/3/13 12:00

Condition: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Drug: Glimepiride; Drug: Vildagliptin
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified March 2013

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

2013/2/13 12:00

Conditions: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Drug: Sulfonylurea (glimepiride); Drug: DPP-4 inhibitor (sitagliptin); Drug: GLP-1 receptor agonist (liraglutide); Drug: Insulin (glargine)
Sponsors: GRADE Study Group; GRADE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Becton, Dickinson and Company; Bristol-Myers Squibb; Merck; Novo Nordisk; Hoffmann-La Roche; Sanofi
Not yet recruiting - verified February 2013

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

2013/1/14 12:00

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: Dulaglutide; Drug: Glimepiride
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified January 2013

Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects

2013/1/13 12:00

Condition: Healthy
Interventions: Drug: Gemigliptin and Glimepiride; Drug: Glimepiride
Sponsors: LG Life Sciences; LG Life Sciences
Not yet recruiting - verified January 2013

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

2012/12/18 12:00

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3012; Drug: Matching placebo to MK-3012; Drug: Glimepiride; Drug: Matching placebo to glimepiride; Drug: Insulin glargine; Drug: Metformin
Sponsors: Merck; Merck
Not yet recruiting - verified December 2012